Protulišmanijski učinak iscrpka biljke Peganum harmala na in vitro rast promastigota Leishmania major u odnosu na trovalentne pripravke antimona by Mohammad Mirzaie et al.
365ISSN 0372-5480Printed in Croatia
Veterinarski arhiV 77 (4), 365-375, 2007
Antileishmanial activity of Peganum harmala extract on the in vitro 
growth of Leishmania major promastigotes in comparison to a 
trivalent antimony drug
Mohammad Mirzaie1*, Seyyed Jafar Nosratabadi2, Amin Derakhshanfar1, 
and Iraj Sharifi2
1Department of Pathobiology, school of Veterinary Medicine, shahid Bahonar University of kerman, kerman, 
iran
2Department of Parasitology and Mycology, school of Medical sciences, kerman University of Medical 
sciences, kerman, iran
MirzAie, M., S. J. NoSrAtAbADi, A. DerAkhShANfAr, i. ShArifi: 
Antileishmanial activity of Peganum harmala extract on the in vitro growth of 
Leishmania major promastigotes in comparison to a trivalent antimony drug. Vet. 
arhiv 77, 365-375, 2007.
AbStrACt
Parasites of the genus Leishmania are transmitted by sandflies that ingest the parasite in the amastigote 
stage resident within macrophages, then inoculate the promastigote stage into other hosts. Peganum harmala, or 
Syrian Rue, has pharmacologically active compounds including several alkaloids with antiprotozoal properties, 
which are found especially in the seeds and the roots. In this research, Leishmania major were cultured in vitro, 
then by using a MTT assay, the biological activity of P. harmala extract in comparison to potassium antimonyl 
tartrate [Sb(III)] on L. major promastigotes was assessed. P. harmala extract and Sb(III) solutions for biological 
testing were prepared in PBS at 5000-20000 µg/mL and 62.5-500 µg/mL, respectively. All experiments were 
repeated at least three times in duplicate. For P. harmala extract and Sb(III), the concentration-response curve 
was plotted, from which IC50 values were determined. Both P. harmala extract and Sb(III) inhibited the growth 
of promastigote forms of L. major in vitro after 72 h. of incubation and had an IC50 of 1832.65 ± 89.72 µg/
mL and 17.87 ± 2.05 µg/mL, respectively. Statistical analysis of the results (optical density and inhibitory 
percentage) of the different concentrations of P. harmala extract and Sb(III) showed that there was no significant 
difference between P. harmala extract and Sb(III) (P>0.05) but with a concentration increase of P. harmala 
extract or Sb(III), optical density decreased significantly, while inhibitory percentage increased. The different 
concentrations resulted in different optical densities or inhibitory percentages (P<0.05) so that P. harmala 
extract is effective against L. major in vitro.
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introduction
Parasites of the genus Leishmania are transmitted by sandflies that ingest the parasite 
in the amastigote stage resident within macrophages, and then inoculate the promastigote 
stage into other hosts. Current estimates indicate that parasites of the genus Leishmania 
affect people in 88 countries, with 350 million at risk of contracting the disease and 
with approximately 2 million new cases being reported each year (HAnDMAn, 2000; 
HAnDMAn, 2001). Proven therapies against human leishmaniasis include pentavalent 
antimonials (sodium stibogluconate and meglumine antimoniate), amphotericin B, 
pentamidine, and paromomycin (BERMAn, 1996; BERMAn, 1997). The mentioned drugs 
have the disadvantages of high cost, lack of oral formulation (e.g., amphotericin B can 
be used only intravenously), or serious side effects that require close monitoring of the 
patients (BERMAn, 1997). Also, development of resistance by the parasites have been 
reported (EPhroS et al., 1997; LIRA et al., 1999; BoELAERT et al., 2002), so that new 
therapies are needed to supplement or replace currently available therapies. 
Peganum harmala, or Syrian Rue, is the plant from which harmine was first isolated, 
as well as a source of harmaline and tetrahydroharmine. Total beta-Carboline content runs 
almost 4% by weight in the seeds of Syrian Rue. Ten gr. of Syrian Rue seeds provide about 
400 mg of total beta-Carbolines. Syrian Rue grows in semi-arid conditions such as those 
which obtain in Iran. It originated in Central Asia and is held in high esteem throughout 
Asia Minor as a medicinal plant. The pharmacologically active compounds of P. harmala 
are several alkaloids, which are found especially in the seeds and roots. These include β-
carbolines such as harmine, harmaline (identical with harmidine), harmalol and harman 
and the quinazoline derivatives vasicine and vasicinone. The alkaloidal content of unripe 
seeds is less than that of ripe ones (KAMEL et al., 1970). Alkaloids compounds illustrate 
well the diversity of antiprotozoal compounds found in P. harmala plant, (WrIghT and 
PhIllIPSoN, 1990) and among the several alkaloids, harmaline (harmidine, C13H14n2o) 
has been found to be a major active alkaloid (BUDAVARI and o’NEIl, 1996).
Several different protozoan infections have been shown to be susceptible to P. 
harmala extract in varying degrees, including theileria annulata, theileria hirci, 
theileria sergenti, Babesia bigemina, anaplasma marginale, Babesia equi and Babesia 
cabali (VECHERKIn, 1977; FAn et al., 1997; HU et al., 1997; MIRZAIEDEHAGHI, 2006). The 
objective of the present study was to determine the effect of P. harmala extract compared 
with potassium antimonyl tartrate, a trivalent antimony, on the in vitro growth and viability 
of Leishmania major promastigotes in a cell-free culture.
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Materials and methods
Plant material and extraction. The aerial parts of P. harmala were collected around 
Isfahan province. The plant was taxonomically identified by botanists in the Department 
of Biology (Shiraz University, Shiraz, Iran). An extract of P. harmala was prepared from 
the seeds of the plant according to the method described by MAnSKE and holMES 
(1952). Finally, the resulting concentrated extract was dried below 70 °C in an oven. All 
concentrations of the extract are based on extract dry weight.
antileishmanial drug. Potassium antimonyl tartrate, a trivalent antimonial [Sb(III)], 
was supplied by Sigma (Sigma Chemical Co., St Louis, Mo.).
Parasite and culture. Leishmania major (WHo designation: MRHo/SU/59/P) 
promastigotes were cultured at 25 ± 1 °C to logarithmic phase in D-MEM/F-12 medium 
(Gibco BRL) without phenol red, supplemented by 10% heat inactivated foetal bovine 
serum (FBS), 100 IU/mL penicillin and 100 μg/mL streptomycin, then washed 3 times 
with phosphate-buffered saline (PBS) by centrifugation at 1500 rpm for 10 min at room 
temperature and resuspended at a concentration of 2.5×106 parasites/mL in medium. 
Various concentrations of compounds. Plant extract solutions for biological testing and 
the drug were prepared in PBS at 5000-20000 µg/mL and 62.5-500 µg/mL, respectively.
antileishmanial activity assays (Mtt assay). The antileishmanial activity of the P. 
harmala extract in comparison to potassium antimonyl tartrate was evaluated in vitro 
against the promastigote forms of Leishmania major using a MTT (3-(4,5-dimethylthiazol-
2yl)-2,5-diphenyltetrazolium bromide)-based microassay as a marker of cell viability. The 
MTT assay used was based on that originally described by MoSMAnn (1983) modified by 
NIkS and oTTo (1990). A stock solution of MTT (Sigma Chemical Co., St. Louis, Mo.) 
was prepared by dissolving MIT in phosphate-buffered saline (PBS) at 5 mg/mL and 
storing in the dark at 4 °C for up to 2 weeks before use. For the antileishmanial activity 
assays, 100 µL/well of the culture which contained 2.5×106 cells/mL promastigotes was 
seeded in 96-well flat-bottom plates. Then, 10 µL/well from various concentrations 
of potassium antimonyl tartrate and P. harmala extract were added to duplicate wells 
and plates were incubated for 72 hour at 25 ± 1 °C. The first well of 96 wells was as a 
blank well which only contained of 100 µL culture medium without any plant extract, 
drug or parasite. At the end of incubation, 10 µL of MTT was added to each well and 
plates were incubated for 3 hour at 25 ± 1 °C. Enzyme reaction was then stopped by the 
addition of 100 µL of 50% isopropanol and 10% sodium dodecyl sulfate. The plates were 
incubated for an additional 30 min. under agitation at room temperature. Relative optical 
density (oD) was then measured at a wavelength of 570 nm using a multiwell scanning 
spectrophotometer (ELISA reader). The background absorbance of multiwell plates was 
measured at 690 nm and substract from 570 nm measurement. The absorbance of the 
formazan produced by the action of mitochondrial dehydrogenases of metabolically 
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active cells is shown to correlate with the number of viable cells (MoSMAnn, 1983; NIkS 
and oTTo, 1990; MAARoUF et al., 1997; SErENo and lEMESrE, 1997; AVLonITIS et al., 
2003). All experiments were repeated at least three times.
Data analysis. The results of each experiment were analyzed by the method 
described by HUBER and KoELLA (1993). For calculation of IC50, they used the following 
mathematical formula:
log(IC50) = log(x1) + [(y1 - y0/2)/(y1 - y2)] [log(x2) - log(x1)].
Briefly, HUBER and KoELLA (1993) proposed finding two concentrations, x1 and x2, 
such that the parasite density, y1, at concentration x1 (and all lower concentrations) was 
more than half of the density found in the control, y0, and that the parasite density, y2, at 
concentration x2 (and all higher concentrations) was less than half of y0. The IC50 was 
then found by linear extrapolation between x1 and x2.
The percentage of non-viable organisms which failed to metabolize MTT and therefore 
did not produce the formazan product was determined by applying the following formula 
(BAnSAL et al., 2004): Percentage of non-viable organisms or inhibitory percentage at 
each compound concentration = 100 - (Test oD - Blank oD/ Control oD - Blank oD) × 
100. 
statistical analysis. The univariate analysis of variance (Univariate AnoVA) and 
the Student’s t-test, with significance at P values of <0.05, were used to compare the 
antileishmanial activity of the P. harmala extract with potassium antimonyl tartrate. For P. 
harmala extract and potassium antimonyl tartrate, the concentration-response curve was 
plotted, from which IC50 values (50% inhibitory concentrations) were determined.
results
antileishmanial assays. Both P. harmala extract and potassium antimonyl tartrate 
inhibited the growth of promastigote forms of L. major in vitro after 72 h. of incubation, 
and had a 50% inhibitory concentration (IC50) of 1832.65 ± 89.72 µg/mL and 17.87 ± 2.05 
µg/mL, respectively. Details of the in vitro inhibitory effect of different concentrations 
of P. harmala extract and potassium antimonyl tartrate against Leishmania major 
promastigotes are presented in Figs. 1. and 2. Also, details of reducing optical density, 
caused by the antileishmanial activity of different concentrations of P. harmala extract and 
potassium antimonyl tartrate on the in vitro growth of Leishmania major promastigotes, 
are presented in Figs. 3. and 4.
Using univariate AnoVA statistical analysis on the results (optical density and 
inhibitory percentage) of the different concentrations of P. harmala extract and potassium 
antimonyl tartrate it was shown that there was no significant difference between P. 
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Fig. 2. Inhibitory effects of different concentrations of potassium antimonyl tartrate on the in vitro 
growth of L. major promastigotes
Fig. 1. Inhibitory effects of different concentrations of P. harmala extract on the in vitro growth of 
L. major promastigotes
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Fig. 4. Reducing optical density caused by antileishmanial activity of different concentrations of 
potassium antimonyl tartrate on the in vitro growth of L. major promastigotes
Fig. 3. Reducing optical density caused by antileishmanial activity of different concentrations of 
P. harmala extract on the in vitro growth of L. major promastigotes
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harmala extract and potassium antimonyl tartrate (P>0.05). However, with a concentration 
increase of P. harmala extract or potassium antimonyl tartrate, optical density significantly 
decreased and inhibitory percentage increased, and the different concentrations resulted 
in different optical densities or inhibitory percentages (P<0.05). Also, the Student’s t 
test analyzed on the inhibitory percentages of the different concentrations of P. harmala 
extract and potassium antimonyl tartrate on the in vitro growth of L. major promastigotes, 
showed that there was no significant difference between P. harmala extract and potassium 
antimonyl tartrate (P>0.05).
Discussion
The results of this research show the antileishmanial activity of P. harmala extract 
(Syrian rue) against Leishmania major in vitro. To our knowledge, based on a search of 
the literature, no studies have been conducted on the effects of P. harmala extract (Syrian 
rue) on the in vitro growth of Leishmania major promastigotes.
There is a general lack of effective and inexpensive chemotherapeutic agents for 
the treatment of leishmaniasis. Although trivalent antimonial [Sb(III)] like potassium 
antimonyl tartrate and pentavalent antimonial drugs are the first-line treatment for this 
disease, with amphotericin B and pentamidine being used as alternative drugs, all of 
these have serious side effects and resistance has become a severe problem. Therefore, 
new drugs are urgently required. natural products have potential in the search for new 
and selective agents for the treatment of important tropical diseases caused by protozoans 
(WrIghT and PhIllIPSoN, 1990). 
The in vivo efficiencies of drugs have been reported to be under the control of different 
parameters, such as pharmacokinetic parameters (SErENo and lEMESrE, 1997), so that 
for various reasons, including simplicity in in vitro culture maintenance, routine screenings 
of antileishmanial chemotherapeutic agents are often based on promastigote susceptibility 
assays (GUPTA et al., 2001). In this report, a relevant viability test (MTT) was used to 
investigate the inhibitory effect of P. harmala extract on the in vitro growth of Leishmania 
major promastigotes. Previous in vitro experiments with L. mexicana promastigotes 
demonstrated that antimony sodium gluconate (Triostam), a trivalent analog of sodium 
stibogluconate, had a 50% lethal dose of 20 µg of Sb(III)/mL (MoTTRAM and CooMBS, 
1985). other investigators have shown that trivalent antimonial compounds were highly 
toxic to different Leishmania species in the promastigote form at concentrations ranging 
from 1.58 to 35.00 µg of Sb(III)/mL (MoTTRAM and CooMBS, 1985; RoBERTS and 
RAInEy, 1993; RoBERTS et al., 1995). Potassium antimony (III) tartrate was shown to be 
substantially more potent than sodium stibogluconate against promastigotes (RoBERTS 
and RAInEy, 1993; RoBERTS et al., 1995), so that in this research potassium antimony 
(III) tartrate at concentrations ranging from 6.25 to 50.00 µg of Sb(III)/mL was used 
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to compare the antileishmanial activity of P. harmala extract against Leishmania major 
promastigotes.
Although the antiprotozoan mechanism of P. harmala extract is as yet unknown, 
several studies have shown that different protozoan infections have been susceptible 
to P. harmala extract in varying degrees, including theileria annulata, theileria hirci, 
theileria sergenti, Babesia bigemina, anaplasma marginale, Babesia equi and Babesia 
cabali (VECHERKIn, 1977; FAn et al., 1997; HU et al., 1997; MIRZAIEDEHAGHI, 2006). 
Alkaloid compounds illustrate well the diversity of antiprotozoal compounds found in 
P. harmala plant (WrIghT and PhIllIPSoN, 1990), and among the several alkaloids 
(harmine, harmaline, harmalol, harman, vasicine and vasicinon) derived from P. harmala 
extract, harmaline (harmidine, C13H14n2o) has been found to be major active alkaloid 
and quite soluble in dilute acids (BUDAVARI and o’NEIl, 1996). In this research, distilled 
water and acetic acid have been used for the plant extraction (MAnSKE and holMES, 
1952) and it is shown that this plant extract contains a high quantity of harmaline and is 
therefore very effective against Leishmania major promastigotes. Also, we demonstrated 
that P. harmala extract demonstrated excellent antileishmanial activity against Leishmania 
major promastigotes in vitro. Potassium antimonyl tartrate at concentrations ranging from 
6.25 to 50.00 µg of Sb(III)/mL, which has been used in this research, is highly toxic 
and effective against Leishmania major promastigotes (MoTTRAM and CooMBS, 1985; 
RoBERTS and RAInEy, 1993; RoBERTS et al., 1995) and statistical analysis of the results 
showed that there was no significant difference between P. harmala extract and potassium 
antimonyl tartrate (P>0.05). Consequently, P. harmala extract is very effective against 
Leishmania major promastigotes in vitro.
In this study, the results showed that with a concentration increase of P. harmala extract 
or potassium antimonyl tartrate, while the inhibitory effect on the growth of Leishmania 
major promastigotes will be increased, relative optical density will be decreased. The 
reason for oD decrease is a decrease of formazan, which is produced by the action of 
mitochondrial dehydrogenases of metabolically active cells and is shown to correlate 
with the number of viable cells (MoSMAnn, 1983; NIkS and oTTo, 1990; MAARoUF et 
al., 1997; SErENo and lEMESrE, 1997; AVLonITIS et al., 2003).
Therapeutic evaluations for medicinal plants are essential because of the growing 
interest in alternative therapies and the therapeutic use of natural products. natural 
products can be lead compounds, allowing the design and rational planning of new drugs, 
biomimetic synthesis development, and the discovery of new therapeutic properties not 
yet attributed to known compounds (HAMBURGER and HoSTETTMAnn, 1991). natural 
products have made, and are continuing to make, an important contribution to this area 
of therapeutics. Perhaps their future potential will be even greater. In this study we 
report the inhibitory effect of P. harmala extract on the in vitro growth of Leishmania 
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major promastigotes. This activity represents an exciting advance in the search for novel 
antileishmanial agents from natural sources, since a significant and important effect 
against the promastigote form of the protozoan was demonstrated. Although this plant 
showed significant activity against Leishmania major promastigotes in vitro, further 
synthesis and in vivo studies are indicated to validate these results. 
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SAŽETAK
Parazite roda Leishmania prenose papatači preko makrofaga zaraženih amastigotima, a nakon razvoja 
nastale promastigote prenose na druge domaćine. Biljka Peganum harmala ili sirijska rutvica posjeduje 
farmakološki aktivne sastojke uključujući nekoliko alkaloida s protuprotozojskom učinkovitošću, koji se 
osobito nalaze u sjemenkama i korijenu biljke. Za potrebe ovog istraživanja, protozoon Leishmania major 
uzgojen je in vitro. Učinak iscrpka biljke P. harmala na promastigote L. major u odnosu na kalijev antimonil-
tartarat [Sb(III)] određen je MTT metodom. Iscrpak P. harmala bio je pripravljen u PBS-u u koncentraciji od 
5.000-20.000 µg/mL. Antimonski pripravak bio je pripravljen u PBS-u u koncentraciji od 62,5-500 µg/mL. 
Svaki pokus in vitro bio je ponovljen najmanje tri puta. Dobiveni rezultati prikazani su krivuljom učinkovitosti 
kojom su određene vrijednosti inhibitorne koncentracije (IC50). oba su pripravka kočila rast promastigota in 
vitro nakon 72 sata. Vrijednost IC50 za iscrpak P. harmala iznosila je 1832,65 ± 89,72 µg/mL. Vrijednost IC50 
za antimonski pripravak iznosila je 17,87 ± 2,05 µg/mL. Statističkom obradom rezultata (optička gustoća i 
postotak inhibicije) dobivenim inkubiranjem protozoa u različitim koncentracijama pripravaka nisu utvrđene 
značajne razlike (P>0,05). Više koncentracije iscrpka P. harmala imale su za posljedicu značajno smanjenje 
optičke gustoće te istovremeno povećanje postotka inhibicije. S obzirom da su različite koncentracije rezultirale 
različitom optičkom gustoćom ili postotkom inhibicije (P<0,05) zaključuje se da iscrpak P. harmala djeluje in 
vitro na vrstu L. major.
Ključne riječi: protulišmanijska učinkovitost, Leishmania major, Peganum harmala, kalijev antimonil- 
tartarat
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